State of New Jersey Common Pension Fund D Sells 53,874 Shares of Hologic, Inc. (NASDAQ:HOLX)

State of New Jersey Common Pension Fund D lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 41.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 76,288 shares of the medical equipment provider’s stock after selling 53,874 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Hologic were worth $5,664,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Innealta Capital LLC bought a new position in shares of Hologic in the 2nd quarter worth approximately $25,000. iA Global Asset Management Inc. bought a new position in shares of Hologic in the 1st quarter worth approximately $37,000. Mather Group LLC. bought a new position in shares of Hologic in the 1st quarter worth approximately $48,000. Massmutual Trust Co. FSB ADV raised its position in shares of Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 137 shares in the last quarter. Finally, Toth Financial Advisory Corp raised its position in shares of Hologic by 81.1% in the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 347 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Activity

In other news, insider Brandon Schnittker sold 476 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock valued at $1,469,973 in the last ninety days. 1.75% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HOLX. Evercore ISI increased their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 30th. StockNews.com upgraded Hologic from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. Stephens restated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Finally, JPMorgan Chase & Co. upped their price target on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.60.

Hologic Stock Performance

Shares of HOLX opened at $81.15 on Monday. The business’s fifty day simple moving average is $80.20 and its two-hundred day simple moving average is $76.86. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The company has a market cap of $18.85 billion, a price-to-earnings ratio of 41.40, a P/E/G ratio of 2.53 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.93 EPS. Research analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.